Gram Positive Bacteria Infection
Conditions
Interventions
experimental group:ATM-guided dosing
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. There is no restriction on gender, age and weight; 2. The clinical symptoms, signs, laboratory examinations and pathogenic microbial examinations have been confirmed to be methicillin-resistant staphylococcus aureus, coagulase-negative staphylococcus, enterococcus, streptococcus viridans (endocarditis) and other aerobic bloodstream infections, infective endocarditis, lung infections (including community-acquired pneumonia, hospital-acquired pneumonia) caused by gram-positive bacteria, complicated abdominal infections, central nervous system infections, skin and soft tissue infections, urinary tract infections (Including acute pyelonephritis, complicated urinary tract infection), bone and joint infections and other patients, and the above-mentioned infections caused by gram-positive bacteria allergic to ß-lactam antibiotics; 3. Those who apply ATM technology for individualized and precise vancomycin medication and perform blood concentration detection; 4. The course of vancomycin treatment is more than 5 days; 5. Those who have obtained informed consent.
Exclusion criteria
Exclusion criteria: 1. Within 3 days before vancomycin treatment and combined or expected to use nephrotoxic drugs during the study period (such as polymyxin drugs, aminoglycoside drugs, etc.); 2. Within 72 hours before selection, had received effective drugs for the treatment of methicillin-resistant staphylococcus and other gram-positive cocci, such as norvancomycin, teicoplanin, linezolid, fusidic acid, tigecycline , Daptomycin and other systemic antibacterial treatment for more than 24 hours; 3. Gram-positive bacteria such as MSSA or methicillin-resistant Staphylococcus are colonizing bacteria; 4. Pregnant or breastfeeding women; 5. Those who lack clinical and laboratory evaluation indicators for infection, and cannot evaluate safety and efficacy; 6. Participants in other clinical trials in the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute Kidney Injury Incidence; | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy; | — |
Countries
China
Contacts
Public ContactZhang Jing
Huashan Hospital, Fudan University
Outcome results
None listed